Thiol-ene polymerization with vinylesters and vinylcarbonate

US9623145B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-9623145-B2
Application numberUS-201213627399-A
CountryUS
Kind codeB2
Filing dateSep 26, 2012
Priority dateOct 3, 2011
Publication dateApr 18, 2017
Grant dateApr 18, 2017

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

The present disclosure is directed, in part, to a curable composition, a method for augmenting a structure in a patient with a resorbable biocompatible polymer, and a biodegradable, resorbable implant comprising a biocompatible copolymer. An exemplary embodiment of the curable composition comprises (a) 60 wt. % to 95 wt. % of one or more vinyl ester monomers and/or vinylcarbonate monomers, wherein said one or more vinyl ester monomers and/or vinylcarbonate monomers are respectively selected from compounds of the general formulas (I) and (II) below: wherein n, m R 1 and R 2 have the meaning defined herein; (b) 0.1 to 40 wt. % of one or more multifunctional thiols; and (c) 0 to 10 wt. % of a biocompatible polymerization initiator.

First claim

Opening claim text (preview).

The invention claimed is: 1. A curable composition comprising: (a) 60 wt. % to 95 wt. % of one or more vinyl ester monomers, wherein said one or more vinyl ester monomers are selected from: (i) a vinyl ester monomer having a formula of wherein n is an integer from 1 to 12; (ii) monomers selected from diethylene glycol bis[O—(O′-vinylmaleinoyl)-polylactate]) (DVMPL); ω,ω′-3,6,9-trioxaundecanedioic acid divinyl ester (TUVE); polyglutamic acid; polyaspartic acid; hyaluronic acid; polylactic acid; polyglycolic acid; and poly(lactide-co-glycolide); (iii) or combinations thereof; (b) 0.1 to 40 wt. % of one or more multifunctional thiols selected from the group consisting of ethoxylated pentaerythritol tetra-(3-mercaptopropionate); trimethylpropane tri(3-mercapto-propionate); ethoxylated trimethylpropane tri(3-mercapto-propionate); glycol dimercaptoacetate; trimethylolpropane trimercaptoacetate; pentaerythritol tetramercaptoacetate; ethoxylated trimethylolpropane tri-3-mercaptopropionate; and ethoxylated trimethylolpropane tri-3-mercaptopropionate; polypropylene glycol (3-mercaptopropionate); polypropylene glycol (3-mercaptopropionate); and (c) 0 to 10 wt. % of a biocompatible polymerization initiator. 2. The curable composition according to claim 1 , wherein at least one of the vinyl ester monomers accounts for 50 mole percent of all monomers contained. 3. The curable composition of claim 1 , wherein said one or more vinyl ester monomers are selected from the group consisting of: 4. A method for augmenting or filling a structure in a patient comprising, (a) implanting a curable composition into said patient at a site of the structure, wherein the implanting step is performed by injecting the curable composition through a hole in the patient's skin and into a vertebra, the curable composition comprising: (aa) 60 wt. % to 95 wt. % of one or more vinyl ester monomers, wherein said one or more vinyl ester monomers are selected from compounds of the general formula (I) below: wherein n independently ranges from 2 to 1000; R 1 is independently selected from the group consisting of: (i) n-valent radicals, each of said n-valent radicals comprising a carbon chain or a carbon cycle or both, wherein said carbon chain and/or carbon cycle each, independently from one another, comprises from 1 to 30 carbon atoms, wherein said carbon chain can be straight, branched, saturated or unsaturated, and containing one or more interspersed heteroatoms, said heteroatoms being selected from the group consisting of oxygen, sulfur and nitrogen, and wherein said carbon chain optionally being substituted with one or more substituents selected from the group consisting of —OH, —COOH, —CN, —CHO, and ═O, wherein said carbon cycle can be saturated or unsaturated, and containing one or more interspersed heteroatoms, said heteroatoms being selected from the group consisting of oxygen, sulfur and nitrogen, and wherein said carbon cycle optionally being substituted with one or more substituents selected from the group consisting of —OH, —COOH, —CN, —CHO, and ═O, and (ii) n-valent radicals of biodegradable, biocompatible oligomers and polymers, said oligomers and polymers being selected from the group consisting of polysaccharides, polypeptides, polyamides, polyesters, polycarbonates, polyethers, and fatty acid derivatives; (bb) 0.1 to 40 wt. % of one or more multifunctional thiols; and (cc) 0 to 10 wt. % of a biocompatible polymerization initiator; (b) initiating said composition to thereby form a resorbable, biocompatible polymer. 5. The method of claim 4 , wherein said initiating is performed by irradiating said curable composition. 6. The method of claim 5 , wherein said irradiating is performed using an optical fiber inserted at the site of the structure. 7. The method of claim 5 , wherein the implanting step has the additional steps of: inserting a balloon through the hole in the patient's skin into the vertebra; inflating the balloon to create a void at the site of the structure. 8. The method of claim 4 , wherein the structure is located at a site of one or more of the following: a fracture, a deformity, a void, and a tumor. 9. A biodegradable implant comprising: a copolymer having monomer units of: (a) 60 wt. % to 95 wt. % of one or more vinyl ester monomers wherein said one or more vinyl ester monomers are selected from: (i) a vinyl ester monomer having a formula of wherein n is an integer from 1 to 12; and (ii) monomers selected from diethylene glycol bis[O—(O′-vinylmaleinoyl)-polylactate]) (DVMPL); ω,ω′-3,6,9-trioxaundecanedioic acid divinyl ester (TUVE); polyglutamic acid; polyaspartic acid; hyaluronic acid; polylactic acid; polyglycolic acid; and poly(lactide-co-glycolide); (iii) or combinations thereof; and (b) 0.1 to 40 wt. % of one or more multifunctional thiols selected from the group consisting of ethoxylated pentaerythritol tetra-(3-mercaptopropionate); trimethylpropane tri(3-mercapto-propionate); ethoxylated trimethylpropane tri(3-mercapto-propionate); glycol dimercaptoacetate; trimethylolpropane trimercaptoacetate; pentaerythritol tetramercaptoacetate; ethoxylated trimethylolpropane tri-3-mercaptopropionate; and ethoxylated trimethylolpropane tri-3-mercaptopropionate; polypropylene glycol (3-mercaptopropionate); polypropylene glycol (3-mercaptopropionate); 10. A method of manufacturing a three-dimensional article through an additive manufacturing process, said method comprising: (a) depositing a layer of a curable composition into a mold of three-dimensional article; (b) directing an energy source to cause radical polymerization of the curable composition to thereby form a cross-section layer of the 3D object/article, the cross-section layer having a thickness ranging from about 0.001 mm to about 3 mm; and (c) repeating steps (a) and (b) to form the three-dimensional article in a layerwise fashion, wherein the curable composition comprises: (aa) 60 wt. % to 95 wt. % of one or more vinyl ester monomers, wherein said one or more vinyl ester monomers are selected from: (i) a vinyl ester monomer having a formula of wherein n is an integer from 1 to 12; and (ii) monomers selected from diethylene glycol bis[O—(O′-vinylmaleinoyl)-polylactate]) (DVMPL); ω,ω′-3,6,9-trioxaundecanedioic acid divinyl ester (TUVE); polyglutamic acid; polyaspartic acid; hyaluronic acid; polylactic acid; polyglycolic acid; and poly(lactide-co-glycolide); (iii) or combinations thereof; (bb) 0.1 to 40 wt. % of one or more multifunctional thiols; and (cc) 0 to 10 wt. % of a biocompatible polymerization initiator. 11. The curable composition according to claim 1 further comprising one or more additives selected from polymerization sensitizers and inhibitors, stabilizers, modifying agents, softeners, dyeing agents, bioactive agents, cells, thickening agents, and fillers. 12. A method for augmenting or filling a structure in a patient comprising, (a)

Assignees

Inventors

Classifications

  • A61L27/16Primary

    obtained by reactions only involving carbon-to-carbon unsaturated bonds · CPC title

  • of esters containing only carbon, hydrogen and oxygen, which oxygen atoms are present only as part of the carboxyl radical · CPC title

  • for reconstruction of bones; weight-bearing implants · CPC title

  • Products made by additive manufacturing · CPC title

  • Biologically active materials, e.g. therapeutic substances {(A61L27/227 takes precedence)} · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US9623145B2 cover?
The present disclosure is directed, in part, to a curable composition, a method for augmenting a structure in a patient with a resorbable biocompatible polymer, and a biodegradable, resorbable implant comprising a biocompatible copolymer. An exemplary embodiment of the curable composition comprises (a) 60 wt. % to 95 wt. % of one or more vinyl ester monomers and/or vinylcarbonate monomers, wher…
Who is the assignee on this patent?
Depuy Synthes Products Inc, Univ Wien Tech
What technology area does this patent fall under?
Primary CPC classification A61L27/16. Mapped technology areas include Human Necessities.
When was this patent published?
Publication date Tue Apr 18 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).